Mammalian target of rapamycin (mTOR) inhibitors, immunosuppressants used in transplant medicine, have been repurposed to target patients with PIK3CA-related vascular malformations and segmental overgrowth. The gene discussed is PIK3CA; the disease is vascular malformation.